BRIEF-CervoMed's Neflamapimod gets U.S. FDA Orphan Drug Designation for treating Frontotemporal Dementia

Reuters
2024-11-27
BRIEF-<a href="https://laohu8.com/S/CRVO">CervoMed</a>'s Neflamapimod gets U.S. FDA Orphan Drug Designation for treating Frontotemporal Dementia

Nov 27 (Reuters) - CervoMed Inc CRVO.O:

  • CERVOMED ANNOUNCES ORPHAN DRUG DESIGNATION GRANTED TO NEFLAMAPIMOD BY U.S. FOOD AND DRUG ADMINISTRATION FOR THE TREATMENT OF FRONTOTEMPORAL DEMENTIA

  • CERVOMED INC - TO REPORT TOPLINE DATA FROM PHASE 2B DLB TRIAL IN DECEMBER 2024

Source text: ID:nGNX3pS5JY

Further company coverage: CRVO.O

((Reuters.Briefs@thomsonreuters.com;))

免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。

熱議股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10